Stockreport

Zymeworks Announces Abstract for Zanidatamab in Late-Line HER2-Positive Breast Cancer at the San Antonio Breast Cancer Symposium (SABCS)

Zymeworks Inc.  (ZYME) 
Last zymeworks inc. earnings: 3/2 04:15 pm Check Earnings Report
US:NYSE Investor Relations: ir.zymeworks.com/overview
PDF Full presentation available December 8 at 5:00 pm Central Time (CT) VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopha [Read more]